Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone-Reference-Cited by-同舟云学术

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone

Published:2016-12 Issue:2 Volume:383 Page:309-317
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Muqbil Irfana,Aboukameel Amro,Elloul Sivan,Carlson Robert,Senapedis William,Baloglu Erkan,Kauffman Michael,Shacham Sharon,Bhutani Divaya,Zonder Jeffrey,Azmi Asfar S.,Mohammad Ramzi M.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Non-Hodgkin lymphoma: diagnosis and treatment;Ansell;Mayo Clin. Proc.,2015

2. Dose-escalation of CHOP in non-Hodgkin lymphoma;Santoro;Ann. Oncol.,1999

3. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin lymphoma;Coiffier;Semin. Oncol.,2002

4. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin lymphoma: results, biology, and development strategies;Schatz;Curr. Oncol. Rep.,2011

5. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel application of XPO1 inhibition for the treatment of myelofibrosis;Blood Neoplasia;2024-06

2. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma;Journal of Experimental & Clinical Cancer Research;2024-05-22

3. Zanubrutinib delays selinexor resistance evolution in biopsy sample-derived primary central nervous system lymphoma models;iScience;2024-05

4. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects;Blood Advances;2023-06-27

5. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1;Biomedicine & Pharmacotherapy;2023-04